Announced Positive Clinical Data for Adult and Pediatric Netherton Patients ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- ...

A diagnosis of Netherton syndrome was made and the patient was started on antihistamines, emollients, and 10% urea. In our case, the patient presented at age 17 years. The history of his ...

Krystal Biotech, Inc.’s KRYS share price has dipped by 12.19%, which has investors questioning if this is right time to buy.

Learn more about whether ACADIA Pharmaceuticals Inc. or BioCryst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

saves approximately $23.5 million over life of loan— —NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11— —U.S. IND open for BCX17725 for Netherton syndrome ...

Key developments include: 1. BCX17225 for Netherton Syndrome: The company is progressing with clinical trials for this rare genetic skin disorder, with data expected later in the year. 2. Avoralstat ...

- Geschätzt 3.000 bis 5.000 Patienten in den USA. - Fokus auf den Nachweis der Krankheitsmodifikation mit BCX 1725. Zusammenfassend ist BioCryst zuversichtlich hinsichtlich seiner strategischen Ausric ...